Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
AnaptysBio Analyst Ratings and Price Targets | NASDAQ:ANAB | Benzinga
AnaptysBio Inc has a consensus price target of $46.46 based on the ratings of 16 analysts. The high is $90 issued by Guggenheim on May 28, 2025. The low is $20 issued by Truist Securities on December 18, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Guggenheim, and Guggenheim on June 4, 2025, May 28, 2025, and May 6, 2025, respectively. With an average price target of $60.67 between HC Wainwright & Co., Guggenheim, and Guggenheim, there's an implied 155.71% upside for AnaptysBio Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Guggenheim
Wedbush
JP Morgan
Wells Fargo
1calculated from analyst ratings
Analyst Ratings for AnaptysBio
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/04/2025 | Buy Now | 60.17% | HC Wainwright & Co. | Emily Bodnar39% | $22 → $38 | Upgrade | Neutral → Buy | Get Alert |
| 05/28/2025 | Buy Now | 279.35% | Guggenheim | Yatin Suneja56% | $54 → $90 | Maintains | Buy | Get Alert |
| 05/06/2025 | Buy Now | 127.61% | Guggenheim | Yatin Suneja56% | $52 → $54 | Maintains | Buy | Get Alert |
| 05/01/2025 | Buy Now | 68.6% | Wedbush | Martin Fan 54% | $40 → $40 | Reiterates | Outperform → Outperform | Get Alert |
| 03/05/2025 | Buy Now | 77.03% | JP Morgan | Anupam Rama59% | $36 → $42 | Maintains | Overweight | Get Alert |
| 03/04/2025 | Buy Now | -7.27% | HC Wainwright & Co. | Emily Bodnar39% | $22 → $22 | Reiterates | Neutral → Neutral | Get Alert |
| 02/13/2025 | Buy Now | 114.96% | Wells Fargo | Derek Archila62% | $40 → $51 | Maintains | Overweight | Get Alert |
| 02/12/2025 | Buy Now | -7.27% | HC Wainwright & Co. | Emily Bodnar39% | $19 → $22 | Maintains | Neutral | Get Alert |
| 02/07/2025 | Buy Now | 68.6% | Wedbush | David Nierengarten61% | $40 → $40 | Maintains | Outperform | Get Alert |
| 02/04/2025 | Buy Now | — | Wolfe Research | Andy Chen46% | — | Initiates | → Outperform | Get Alert |
| 02/04/2025 | Buy Now | -19.92% | HC Wainwright & Co. | Emily Bodnar39% | $19 → $19 | Reiterates | Neutral → Neutral | Get Alert |
| 12/19/2024 | Buy Now | 51.74% | JP Morgan | Anupam Rama59% | $66 → $36 | Maintains | Overweight | Get Alert |
| 12/18/2024 | Buy Now | -15.7% | Truist Securities | John Lee1% | $30 → $20 | Maintains | Hold | Get Alert |
| 12/12/2024 | Buy Now | 68.6% | Wells Fargo | Derek Archila62% | $56 → $40 | Maintains | Overweight | Get Alert |
| 12/12/2024 | Buy Now | 51.74% | Guggenheim | Yatin Suneja56% | $90 → $36 | Maintains | Buy | Get Alert |
| 12/11/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar39% | — | Downgrade | Buy → Neutral | Get Alert |
| 12/02/2024 | Buy Now | — | BTIG | Julian Harrison37% | — | Downgrade | Buy → Neutral | Get Alert |
| 11/12/2024 | Buy Now | 178.19% | JP Morgan | Anupam Rama59% | $75 → $66 | Maintains | Overweight | Get Alert |
| 11/06/2024 | Buy Now | 119.18% | HC Wainwright & Co. | Emily Bodnar39% | $55 → $52 | Maintains | Buy | Get Alert |
| 10/31/2024 | Buy Now | 131.82% | HC Wainwright & Co. | Emily Bodnar39% | $55 → $55 | Reiterates | Buy → Buy | Get Alert |
| 10/30/2024 | Buy Now | 39.09% | UBS | Eliana Merle49% | $23 → $33 | Maintains | Neutral | Get Alert |
| 10/21/2024 | Buy Now | 279.35% | Guggenheim | Yatin Suneja56% | $75 → $90 | Maintains | Buy | Get Alert |
| 09/26/2024 | Buy Now | 77.03% | Wedbush | David Nierengarten61% | $42 → $42 | Reiterates | Outperform → Outperform | Get Alert |
| 08/15/2024 | Buy Now | 26.45% | Truist Securities | John Lee1% | $20 → $30 | Maintains | Hold | Get Alert |
| 08/14/2024 | Buy Now | 131.82% | HC Wainwright & Co. | Emily Bodnar39% | $55 → $55 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2024 | Buy Now | 216.12% | JP Morgan | Anupam Rama59% | $69 → $75 | Maintains | Overweight | Get Alert |
| 08/06/2024 | Buy Now | 131.82% | HC Wainwright & Co. | Emily Bodnar39% | $55 → $55 | Reiterates | Buy → Buy | Get Alert |
| 07/22/2024 | Buy Now | 131.82% | HC Wainwright & Co. | Emily Bodnar39% | → $55 | Initiates | → Buy | Get Alert |
| 07/19/2024 | Buy Now | 190.83% | JP Morgan | Anupam Rama59% | $29 → $69 | Upgrade | Neutral → Overweight | Get Alert |
| 05/10/2024 | Buy Now | 43.31% | Wedbush | David Nierengarten61% | → $34 | Reiterates | Outperform → Outperform | Get Alert |
| 04/16/2024 | Buy Now | 98.1% | Leerink Partners | David Risinger72% | → $47 | Initiates | → Outperform | Get Alert |
| 04/11/2024 | Buy Now | 136.04% | Wells Fargo | Derek Archila62% | → $56 | Initiates | → Overweight | Get Alert |
| 04/01/2024 | Buy Now | 18.02% | JP Morgan | Anupam Rama59% | $30 → $28 | Maintains | Neutral | Get Alert |
| 03/12/2024 | Buy Now | — | Wedbush | David Nierengarten61% | — | Upgrade | Neutral → Outperform | Get Alert |
| 02/26/2024 | Buy Now | 131.82% | BTIG | Julian Harrison37% | → $55 | Initiates | → Buy | Get Alert |
| 02/21/2024 | Buy Now | 110.75% | Stifel | Alex Schwartz42% | → $50 | Initiates | → Buy | Get Alert |
| 02/16/2024 | Buy Now | 237.2% | Piper Sandler | Yasmeen Rahimi59% | → $80 | Initiates | → Overweight | Get Alert |
| 11/29/2023 | Buy Now | -15.7% | Wedbush | David Nierengarten61% | → $20 | Reiterates | Neutral → Neutral | Get Alert |
| 11/03/2023 | Buy Now | -15.7% | Wedbush | David Nierengarten61% | $18 → $20 | Maintains | Neutral | Get Alert |
| 11/02/2023 | Buy Now | -11.49% | UBS | Eliana Merle49% | $28 → $21 | Maintains | Neutral | Get Alert |
| 08/08/2023 | Buy Now | 9.59% | Wedbush | David Nierengarten61% | $29 → $26 | Maintains | Neutral | Get Alert |
| 05/22/2023 | Buy Now | 26.45% | JP Morgan | Anupam Rama59% | $31 → $30 | Upgrade | Underweight → Neutral | Get Alert |
| 05/12/2023 | Buy Now | 22.23% | Wedbush | David Nierengarten61% | → $29 | Reiterates | Neutral → Neutral | Get Alert |
| 05/12/2023 | Buy Now | 89.67% | Guggenheim | Yatin Suneja56% | $44 → $45 | Maintains | Buy | Get Alert |
| 04/12/2023 | Buy Now | 30.66% | JP Morgan | Anupam Rama59% | $32 → $31 | Maintains | Underweight | Get Alert |
| 01/06/2023 | Buy Now | — | Raymond James | Timur Ivannikov37% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 11/18/2022 | Buy Now | 34.88% | JP Morgan | Anupam Rama59% | $24 → $32 | Maintains | Underweight | Get Alert |
| 11/09/2022 | Buy Now | 60.17% | Raymond James | Steven Seedhouse57% | $30 → $38 | Maintains | Outperform | Get Alert |
| 11/01/2022 | Buy Now | — | Guggenheim | Yatin Suneja56% | — | Upgrade | Neutral → Buy | Get Alert |
| 09/19/2022 | Buy Now | 47.52% | HC Wainwright & Co. | Gobind Singh19% | → $35 | Assumes | → Buy | Get Alert |
| 09/13/2022 | Buy Now | 18.02% | Truist Securities | John Lee1% | $50 → $28 | Downgrade | Buy → Hold | Get Alert |
| 09/01/2022 | Buy Now | 47.52% | Raymond James | Steven Seedhouse57% | → $35 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for AnaptysBio (ANAB) stock?
The latest price target for AnaptysBio (NASDAQ:ANAB) was reported by HC Wainwright & Co. on June 4, 2025. The analyst firm set a price target for $38.00 expecting ANAB to rise to within 12 months (a possible 60.17% upside). 29 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for AnaptysBio (ANAB)?
The latest analyst rating for AnaptysBio (NASDAQ:ANAB) was provided by HC Wainwright & Co., and AnaptysBio upgraded their buy rating.
When was the last upgrade for AnaptysBio (ANAB)?
The last upgrade for AnaptysBio Inc happened on June 4, 2025 when HC Wainwright & Co. raised their price target to $38. HC Wainwright & Co. previously had a neutral for AnaptysBio Inc.
When was the last downgrade for AnaptysBio (ANAB)?
The last downgrade for AnaptysBio Inc happened on December 11, 2024 when HC Wainwright & Co. changed their price target from N/A to N/A for AnaptysBio Inc.
When is the next analyst rating going to be posted or updated for AnaptysBio (ANAB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AnaptysBio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AnaptysBio was filed on June 4, 2025 so you should expect the next rating to be made available sometime around June 4, 2026.
Is the Analyst Rating AnaptysBio (ANAB) correct?
While ratings are subjective and will change, the latest AnaptysBio (ANAB) rating was a upgraded with a price target of $22.00 to $38.00. The current price AnaptysBio (ANAB) is trading at is $23.73, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
